Nature Communications (Mar 2022)
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
- Simeng Lin,
- Nicholas A. Kennedy,
- Aamir Saifuddin,
- Diana Muñoz Sandoval,
- Catherine J. Reynolds,
- Rocio Castro Seoane,
- Sherine H. Kottoor,
- Franziska P. Pieper,
- Kai-Min Lin,
- David K. Butler,
- Neil Chanchlani,
- Rachel Nice,
- Desmond Chee,
- Claire Bewshea,
- Malik Janjua,
- Timothy J. McDonald,
- Shaji Sebastian,
- James L. Alexander,
- Laura Constable,
- James C. Lee,
- Charles D. Murray,
- Ailsa L. Hart,
- Peter M. Irving,
- Gareth-Rhys Jones,
- Klaartje B. Kok,
- Christopher A. Lamb,
- Charlie W. Lees,
- Daniel M. Altmann,
- Rosemary J. Boyton,
- James R. Goodhand,
- Nick Powell,
- Tariq Ahmad,
- CLARITY IBD study
Affiliations
- Simeng Lin
- Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust
- Nicholas A. Kennedy
- Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust
- Aamir Saifuddin
- Department of Gastroenterology, St Marks Hospital and Academic Institute
- Diana Muñoz Sandoval
- Department of Infectious Disease, Imperial College London
- Catherine J. Reynolds
- Department of Infectious Disease, Imperial College London
- Rocio Castro Seoane
- Department of Immunology and Inflammation, Imperial College London
- Sherine H. Kottoor
- Department of Metabolism, Digestion and Reproduction, Imperial College London
- Franziska P. Pieper
- Department of Infectious Disease, Imperial College London
- Kai-Min Lin
- Department of Infectious Disease, Imperial College London
- David K. Butler
- Department of Infectious Disease, Imperial College London
- Neil Chanchlani
- Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust
- Rachel Nice
- Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter
- Desmond Chee
- Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust
- Claire Bewshea
- Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter
- Malik Janjua
- Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust
- Timothy J. McDonald
- Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust
- Shaji Sebastian
- IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust
- James L. Alexander
- Department of Metabolism, Digestion and Reproduction, Imperial College London
- Laura Constable
- Department of Metabolism, Digestion and Reproduction, Imperial College London
- James C. Lee
- Department of Gastroenterology, Royal Free London NHS Foundation Trust
- Charles D. Murray
- Department of Gastroenterology, Royal Free London NHS Foundation Trust
- Ailsa L. Hart
- Department of Gastroenterology, St Marks Hospital and Academic Institute
- Peter M. Irving
- Department of Gastroenterology, Guy’s and St Thomas’ NHS Foundation Trust
- Gareth-Rhys Jones
- Department of Gastroenterology, Western General Hospital, NHS Lothian
- Klaartje B. Kok
- Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust
- Christopher A. Lamb
- Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust
- Charlie W. Lees
- Department of Gastroenterology, Western General Hospital, NHS Lothian
- Daniel M. Altmann
- Department of Immunology and Inflammation, Imperial College London
- Rosemary J. Boyton
- Department of Infectious Disease, Imperial College London
- James R. Goodhand
- Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust
- Nick Powell
- Department of Metabolism, Digestion and Reproduction, Imperial College London
- Tariq Ahmad
- Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust
- CLARITY IBD study
- DOI
- https://doi.org/10.1038/s41467-022-28517-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Vaccination is effective in protecting from COVID-19. Here the authors report immune responses and breakthrough infections in twice-vaccinated patients receiving anti-TNF treatments for inflammatory bowel disease, and find dampened vaccine responses that implicate the need of adapted vaccination schedules for these patients.
